For example, inhibition of DRP 1 by either a putative DRP inhibitor (e.g., Mdivi-1) or DRP1 silencing increased the cisplatin sensitivity of hypoxic ovarian cancer cells [455,466]. The gene discussed is DNM1L; the disease is ovarian carcinoma.